Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) – Pipeline Review, H1 2018
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) – Pipeline Review, H1 2018
SUMMARY
According to the recently published report 'Growth Hormone Secretagogue Receptor Type 1 – Pipeline Review, H1 2018'; Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) pipeline Target constitutes close to 20 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes.
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) – Growth hormone secretagogue receptor (GHSR) also known as ghrelin receptor, is a G protein-coupled receptor that binds ghrelin. Ghrelin is an appetite-regulating factor secreted from peripheral organs via binding to the receptor resulting in the secretion of growth hormone by the pituitary gland.
The pathway activated by binding of ghrelin to the growth hormone secretagogue receptor, GHSR1a, regulates the activation of the downstream mitogen-activated protein kinase, Akt, nitric oxide synthase, and AMPK cascades in different cellular systems. Inverse agonists for the ghrelin receptor could be particularly interesting for the treatment of obesity.
The report 'Growth Hormone Secretagogue Receptor Type 1 – Pipeline Review, H1 2018' outlays comprehensive information on the Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4, 1, 9 and 3 respectively. Similarly, the universities portfolio in Phase II stages comprises 1 molecules, respectively.
Report covers products from therapy areas Oncology, Toxicology, Metabolic Disorders, Central Nervous System, Cardiovascular, Gastrointestinal, Genetic Disorders, Genito Urinary System And Sex Hormones, Hormonal Disorders and Infectious Disease which include indications Cancer Anorexia-Cachexia Syndrome, Obesity, Prader-Willi Syndrome (PWS), Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), Acute Ischemic Stroke, Alcohol Addiction, Chemotherapy Effects, Chemotherapy Induced Peripheral Neuropathy, Chronic Kidney Disease (Chronic Renal Failure), Diabetes, Diabetic Gastroparesis, Fatigue, Growth Hormone Deficiency, Ischemia, Opioid-Induced Bowel Dysfunction (OBD or OIBD), Sepsis and Traumatic Brain Injury.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
SUMMARY
According to the recently published report 'Growth Hormone Secretagogue Receptor Type 1 – Pipeline Review, H1 2018'; Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) pipeline Target constitutes close to 20 molecules. Out of which approximately 19 molecules are developed by companies and remaining by the universities/institutes.
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) – Growth hormone secretagogue receptor (GHSR) also known as ghrelin receptor, is a G protein-coupled receptor that binds ghrelin. Ghrelin is an appetite-regulating factor secreted from peripheral organs via binding to the receptor resulting in the secretion of growth hormone by the pituitary gland.
The pathway activated by binding of ghrelin to the growth hormone secretagogue receptor, GHSR1a, regulates the activation of the downstream mitogen-activated protein kinase, Akt, nitric oxide synthase, and AMPK cascades in different cellular systems. Inverse agonists for the ghrelin receptor could be particularly interesting for the treatment of obesity.
The report 'Growth Hormone Secretagogue Receptor Type 1 – Pipeline Review, H1 2018' outlays comprehensive information on the Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type; that are being developed by Companies/Universities.
It also reviews key players involved in Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics development with respective active and dormant or discontinued projects. Currently, The molecules developed by companies in Filing rejected/Withdrawn, Phase III, Phase II, Phase I, Preclinical and Discovery stages are 1, 1, 4, 1, 9 and 3 respectively. Similarly, the universities portfolio in Phase II stages comprises 1 molecules, respectively.
Report covers products from therapy areas Oncology, Toxicology, Metabolic Disorders, Central Nervous System, Cardiovascular, Gastrointestinal, Genetic Disorders, Genito Urinary System And Sex Hormones, Hormonal Disorders and Infectious Disease which include indications Cancer Anorexia-Cachexia Syndrome, Obesity, Prader-Willi Syndrome (PWS), Radiation Toxicity (Radiation Sickness, Acute Radiation Syndrome), Acute Ischemic Stroke, Alcohol Addiction, Chemotherapy Effects, Chemotherapy Induced Peripheral Neuropathy, Chronic Kidney Disease (Chronic Renal Failure), Diabetes, Diabetic Gastroparesis, Fatigue, Growth Hormone Deficiency, Ischemia, Opioid-Induced Bowel Dysfunction (OBD or OIBD), Sepsis and Traumatic Brain Injury.
Note: Certain content/sections in the pipeline guide may be removed or altered based on the availability and relevance of data.
SCOPE
- The report provides a snapshot of the global therapeutic landscape for Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)
- The report reviews Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved in Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics and enlists all their major and minor projects
- The report assesses Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news and deals related to Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) targeted therapeutics
- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand the targeted therapy areas and indications for Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR)
- Identify the use of drugs for target identification and drug repurposing
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) development landscape
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
Introduction
Global Markets Direct Report Coverage
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) – Overview
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) – Companies Involved in Therapeutics Development
Aeterna Zentaris Inc
Allergan Plc
AstraZeneca Plc
Daiichi Sankyo Co Ltd
Millendo Therapeutics Inc
Oxeia Biopharmaceuticals Inc
Pfizer Inc
RaQualia Pharma Inc
Zeria Pharmaceutical Co Ltd
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) – Drug Profiles
anamorelin hydrochloride – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZ-12861903 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZP-531 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EXT-400 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EXT-405 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-01 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-03 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-04 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ibutamoren mesylate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
macimorelin acetate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OXE-103 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Agonize GHSR for Acute Ischemic Stroke, Acute Radiation Syndrome and Sepsis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-05190457 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
relamorelin – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RQ-00433412 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Ghrelin Receptor for Obesity – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Ghrelin Receptor for Obesity – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Modulate GHSR for Chronic Kidney Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ulimorelin hydrochloride – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Z-505 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) – Dormant Products
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) – Discontinued Products
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) – Product Development Milestones
Featured News & Press Releases
Jan 23, 2018: Lyric Pharmaceuticals Presents Data at ASPEN Conference on the Incidence of Enteral Feeding Intolerance in the ICU
Jan 17, 2018: Lyric Pharma Granted FDA Fast Track Designation for Lead Product Ulimorelin for Enteral Feeding Intolerance
Dec 20, 2017: Aeterna Zentaris Announces FDA Approval of Macrilen (macimorelin) for Diagnosis of Adult Growth Hormone Deficiency
Nov 27, 2017: Aeterna Zentaris Marketing Authorization Application for Macrilen (macimorelin) for Evaluation of Adult Growth Hormone Deficiency Accepted by European Medicines Agency
Sep 15, 2017: Refusal of the marketing authorisation for Adlumiz (anamorelin hydrochloride)
Sep 06, 2017: Oxeia Biopharmaceuticals Announces Appointment Of Dr. Michael Wyand As Chief Executive Officer
Aug 23, 2017: Richard Sherman, NFL All-Pro, Joins Oxeia Biopharmaceuticals Advisory Board
Jul 18, 2017: NDA for Macrilen for the Evaluation of Growth Hormone Deficiency in Adults Granted December 30, 2017 PDUFA Date
Jun 30, 2017: Aeterna Zentaris Resubmits NDA for Macrilen for the Evaluation of Growth Hormone Deficiency in Adults
Jun 19, 2017: Ammonett Pharma Granted Orphan Drug Designation From the U.S. FDA for Ibutamoren Mesylate (MK-0677) for Treatment of Growth Hormone Deficiency
May 25, 2017: Ammonett Pharma Receives Notice of Allowance of U.S. Patent for Oratrope Related to Detecting and Treating Growth Hormone Deficiency
May 23, 2017: Ammonett Pharma Receives Positive Opinion from European Orphan Medicinal Products Committee for MK-0677 for Treatment of Pediatric Growth Hormone Deficiency
May 18, 2017: Helsinn Announces Refusal of the marketing authorisation for Adlumiz (anamorelin hydrochloride)
May 01, 2017: Allergan to Present Data on Relamorelin at Digestive Disease Week 2017
Mar 30, 2017: Aeterna Zentaris Intends to File NDA with Respect to Macrilen in Third Quarter of 2017
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
Global Markets Direct Report Coverage
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) – Overview
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) – Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) – Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) – Companies Involved in Therapeutics Development
Aeterna Zentaris Inc
Allergan Plc
AstraZeneca Plc
Daiichi Sankyo Co Ltd
Millendo Therapeutics Inc
Oxeia Biopharmaceuticals Inc
Pfizer Inc
RaQualia Pharma Inc
Zeria Pharmaceutical Co Ltd
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) – Drug Profiles
anamorelin hydrochloride – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZ-12861903 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
AZP-531 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EXT-400 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
EXT-405 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-01 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-03 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
HM-04 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ibutamoren mesylate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
macimorelin acetate – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
OXE-103 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Peptide to Agonize GHSR for Acute Ischemic Stroke, Acute Radiation Syndrome and Sepsis – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
PF-05190457 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
relamorelin – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
RQ-00433412 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Ghrelin Receptor for Obesity – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Small Molecule to Antagonize Ghrelin Receptor for Obesity – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Synthetic Peptide to Modulate GHSR for Chronic Kidney Disease – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
ulimorelin hydrochloride – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Z-505 – Drug Profile
Product Description
Mechanism Of Action
R&D Progress
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) – Dormant Products
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) – Discontinued Products
Growth Hormone Secretagogue Receptor Type 1 (GH Releasing Peptide Receptor or Ghrelin Receptor or GHSR) – Product Development Milestones
Featured News & Press Releases
Jan 23, 2018: Lyric Pharmaceuticals Presents Data at ASPEN Conference on the Incidence of Enteral Feeding Intolerance in the ICU
Jan 17, 2018: Lyric Pharma Granted FDA Fast Track Designation for Lead Product Ulimorelin for Enteral Feeding Intolerance
Dec 20, 2017: Aeterna Zentaris Announces FDA Approval of Macrilen (macimorelin) for Diagnosis of Adult Growth Hormone Deficiency
Nov 27, 2017: Aeterna Zentaris Marketing Authorization Application for Macrilen (macimorelin) for Evaluation of Adult Growth Hormone Deficiency Accepted by European Medicines Agency
Sep 15, 2017: Refusal of the marketing authorisation for Adlumiz (anamorelin hydrochloride)
Sep 06, 2017: Oxeia Biopharmaceuticals Announces Appointment Of Dr. Michael Wyand As Chief Executive Officer
Aug 23, 2017: Richard Sherman, NFL All-Pro, Joins Oxeia Biopharmaceuticals Advisory Board
Jul 18, 2017: NDA for Macrilen for the Evaluation of Growth Hormone Deficiency in Adults Granted December 30, 2017 PDUFA Date
Jun 30, 2017: Aeterna Zentaris Resubmits NDA for Macrilen for the Evaluation of Growth Hormone Deficiency in Adults
Jun 19, 2017: Ammonett Pharma Granted Orphan Drug Designation From the U.S. FDA for Ibutamoren Mesylate (MK-0677) for Treatment of Growth Hormone Deficiency
May 25, 2017: Ammonett Pharma Receives Notice of Allowance of U.S. Patent for Oratrope Related to Detecting and Treating Growth Hormone Deficiency
May 23, 2017: Ammonett Pharma Receives Positive Opinion from European Orphan Medicinal Products Committee for MK-0677 for Treatment of Pediatric Growth Hormone Deficiency
May 18, 2017: Helsinn Announces Refusal of the marketing authorisation for Adlumiz (anamorelin hydrochloride)
May 01, 2017: Allergan to Present Data on Relamorelin at Digestive Disease Week 2017
Mar 30, 2017: Aeterna Zentaris Intends to File NDA with Respect to Macrilen in Third Quarter of 2017
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer
LIST OF TABLES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Aeterna Zentaris Inc, H1 2018
Pipeline by Allergan Plc, H1 2018
Pipeline by AstraZeneca Plc, H1 2018
Pipeline by Daiichi Sankyo Co Ltd, H1 2018
Pipeline by Millendo Therapeutics Inc, H1 2018
Pipeline by Oxeia Biopharmaceuticals Inc, H1 2018
Pipeline by Pfizer Inc, H1 2018
Pipeline by RaQualia Pharma Inc, H1 2018
Pipeline by Zeria Pharmaceutical Co Ltd, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Dormant Products, H1 2018 (Contd.2), H1 2018
Discontinued Products, H1 2018
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Indication, H1 2018
Number of Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018
Products under Development by Companies, H1 2018 (Contd.1), H1 2018
Number of Products under Investigation by Universities/Institutes, H1 2018
Products under Investigation by Universities/Institutes, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Stage and Route of Administration, H1 2018
Number of Products by Stage and Molecule Type, H1 2018
Pipeline by Aeterna Zentaris Inc, H1 2018
Pipeline by Allergan Plc, H1 2018
Pipeline by AstraZeneca Plc, H1 2018
Pipeline by Daiichi Sankyo Co Ltd, H1 2018
Pipeline by Millendo Therapeutics Inc, H1 2018
Pipeline by Oxeia Biopharmaceuticals Inc, H1 2018
Pipeline by Pfizer Inc, H1 2018
Pipeline by RaQualia Pharma Inc, H1 2018
Pipeline by Zeria Pharmaceutical Co Ltd, H1 2018
Dormant Products, H1 2018
Dormant Products, H1 2018 (Contd.1), H1 2018
Dormant Products, H1 2018 (Contd.2), H1 2018
Discontinued Products, H1 2018
LIST OF FIGURES
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
Aeterna Zentaris Inc
Allergan Plc
AstraZeneca Plc
Daiichi Sankyo Co Ltd
Millendo Therapeutics Inc
Oxeia Biopharmaceuticals Inc
Pfizer Inc
RaQualia Pharma Inc
Zeria Pharmaceutical Co Ltd
Number of Products under Development by Stage of Development, H1 2018
Number of Products under Development by Therapy Areas, H1 2018
Number of Products under Development by Top 10 Indications, H1 2018
Number of Products by Mechanism of Actions, H1 2018
Number of Products by Stage and Mechanism of Actions, H1 2018
Number of Products by Routes of Administration, H1 2018
Number of Products by Stage and Routes of Administration, H1 2018
Number of Products by Molecule Types, H1 2018
Number of Products by Stage and Molecule Types, H1 2018
COMPANIES MENTIONED
Aeterna Zentaris Inc
Allergan Plc
AstraZeneca Plc
Daiichi Sankyo Co Ltd
Millendo Therapeutics Inc
Oxeia Biopharmaceuticals Inc
Pfizer Inc
RaQualia Pharma Inc
Zeria Pharmaceutical Co Ltd
